Regimen-related toxicity
| Organ/system . | n (%) . | |||
|---|---|---|---|---|
| Grade I . | Grade II . | Grade III . | Grade IV . | |
| Liver | ||||
| Transaminitis* | 14 (30) | 6 (13) | 17 (37) | 6 (13) |
| Hyperbilirubiniemia | 5 (11) | 1 (2) | 1 (2) | 1 (2) |
| Ascites | 0 | 0 | 3 (7) | 0 |
| Veno-occlusive disease | 0 | 0 | 2 (4) | 0 |
| Gastrointestinal | ||||
| Mucositis | 5 (11) | 15 (33) | 11 (24) | 0 |
| Nausea/vomiting | 5 (11) | 15 (33) | 4 (9) | 0 |
| Diarrhea | 4 (9) | 2 (4) | 4 (9) | 0 |
| Abdominal pain | 0 | 3 (7) | 2 (4) | 0 |
| Genito-urinary | ||||
| Creatinine elevation | 2 (4) | 1 (2) | 0 | 0 |
| Hemorrhagic cystitis | 0 | 0 | 1 (2) | 0 |
| Cardiopulmonary | ||||
| Hypertension | 0 | 0 | 3 (7) | 0 |
| Hypotension | 0 | 1 (2) | 0 | 0 |
| Hypoxia | 0 | 0 | 5 (11) | 1 (2) |
| Neurologic | ||||
| Seizure | 0 | 0 | 1 (2) | 0 |
| Syncope | 0 | 0 | 2 (4) | 0 |
| Headache | 3 (7) | 1 (2) | 0 | 0 |
| Confusion | 0 | 1 (2) | 0 | 0 |
| Skin | ||||
| Hand-foot syndrome | 0 | 3 (7) | 6 (13) | 0 |
| Rash | 0 | 2 (4) | 0 | 0 |
| Constitutional | ||||
| Fever | 0 | 0 | 21 (46) | 0 |
| Musculoskeletal pain | 0 | 0 | 2 (4) | 0 |
| Other | ||||
| Hypersensitivity | 0 | 0 | 1 (2) | 0 |
| Thrombosis | 0 | 0 | 2 (4) | 0 |
| Organ/system . | n (%) . | |||
|---|---|---|---|---|
| Grade I . | Grade II . | Grade III . | Grade IV . | |
| Liver | ||||
| Transaminitis* | 14 (30) | 6 (13) | 17 (37) | 6 (13) |
| Hyperbilirubiniemia | 5 (11) | 1 (2) | 1 (2) | 1 (2) |
| Ascites | 0 | 0 | 3 (7) | 0 |
| Veno-occlusive disease | 0 | 0 | 2 (4) | 0 |
| Gastrointestinal | ||||
| Mucositis | 5 (11) | 15 (33) | 11 (24) | 0 |
| Nausea/vomiting | 5 (11) | 15 (33) | 4 (9) | 0 |
| Diarrhea | 4 (9) | 2 (4) | 4 (9) | 0 |
| Abdominal pain | 0 | 3 (7) | 2 (4) | 0 |
| Genito-urinary | ||||
| Creatinine elevation | 2 (4) | 1 (2) | 0 | 0 |
| Hemorrhagic cystitis | 0 | 0 | 1 (2) | 0 |
| Cardiopulmonary | ||||
| Hypertension | 0 | 0 | 3 (7) | 0 |
| Hypotension | 0 | 1 (2) | 0 | 0 |
| Hypoxia | 0 | 0 | 5 (11) | 1 (2) |
| Neurologic | ||||
| Seizure | 0 | 0 | 1 (2) | 0 |
| Syncope | 0 | 0 | 2 (4) | 0 |
| Headache | 3 (7) | 1 (2) | 0 | 0 |
| Confusion | 0 | 1 (2) | 0 | 0 |
| Skin | ||||
| Hand-foot syndrome | 0 | 3 (7) | 6 (13) | 0 |
| Rash | 0 | 2 (4) | 0 | 0 |
| Constitutional | ||||
| Fever | 0 | 0 | 21 (46) | 0 |
| Musculoskeletal pain | 0 | 0 | 2 (4) | 0 |
| Other | ||||
| Hypersensitivity | 0 | 0 | 1 (2) | 0 |
| Thrombosis | 0 | 0 | 2 (4) | 0 |
Recorded National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 3.0 nonhematologic toxicities from initiation of conditioning to day +30 or CTCAE 3.0 toxicities after day +30 possibly, probably, or definitely related to conditioning.
Transient resolving within 14 days.